Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/88149

In Collections

This item can be found in the following collections:

Visser, K.; Allaart, C.F.; Huizinga, T.W.J. (2010)

Use of methotrexate in undifferentiated arthritis

Article / Letter to editor
The prognosis of patients with undifferentiated arthritis (UA) may vary front self-limited to severe destructive rheumatoid arthritis (RA). Based on the chance that these patients will develop RA and based on the safety profile of a course of methotrexate for 30-90 days, many clinicians consider using methotrexate in this patient category using the "n of l" trial principle. During the last few years, more data on interventions in UA have become available that provide guidance in the prescription of drugs to UA patients.
Methotrexate undifferentiated arthritis early rheumatoid-arthritis modifying antirheumatic drugs placebo-controlled trial clinical pharmacogenetic model citrullinated protein antibody prediction rule double-blind radiographic progression treatment strategy randomized-trial
All authors
Visser, K.; Allaart, C.F.; Huizinga, T.W.J.
Date
2010-10-31
Journal
Clinical and Experimental Rheumatology
Volume
28
Issue
5
Pages
S117S121